SANCUSO® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days.
Sancuso is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the transdermal system.
The most common adverse reaction (≥ 3%) is constipation.
You are encouraged to report suspected adverse reactions to Cumberland Pharmaceuticals Inc. at 1-833-Sancuso or FDA at 1-800-FDA-1088 or www.fda.gov/ medwatch.